期刊
NATURE MEDICINE
卷 18, 期 2, 页码 221-223出版社
NATURE RESEARCH
DOI: 10.1038/nm.2609
关键词
-
资金
- Institut de Salud Carlos III (ISCIII) -Subdireccion General de Evaluacion y Fomento de la Investigacion [PS09/01491, PI08/0211, PI09/1285]
- Plan Nacional (PN) de Investigacion Cientifica, Desarrollo e Innovacion Tecnologica (I+D+I), iniciativa Ingenio, programa Consolider
- ISCIII/FEDER [RD06/0020/0109]
- PN de I+D+I [2008-20011]
- DIUE Generalitat de Catalunya [2009 SGR 321]
- FEDER [RD09/0076/00036]
- Xarxa de Bancs de Tumors de Catalunya
- PDO (XBTC)
Antibodies against epidermal growth factor receptor (EGFR)-cetuximab and panitumumab-are widely used to treat colorectal cancer. Unfortunately, patients eventually develop resistance to these agents. We describe an acquired EGFR ectodomain mutation (S492R) that prevents cetuximab binding and confers resistance to cetuximab. Cells with this mutation, however, retain binding to and are growth inhibited by panitumumab. Two of ten subjects studied here with disease progression after cetuximab treatment acquired this mutation. A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据